Developer docs
API playgroundTry for free, no card

Search company profiles

Kanvas Biosciences

Full company profile

uuid0000u9z

Namestring
Kanvas Biosciences
Legal namestring
Kanvas Biosciences, Inc.
Websiteurl
kanvasbio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Kanvas Biosciences is a clinical-stage biotechnology company developing live biotherapeutic products (LBPs) for immuno-oncology, immune-related adverse events, and global health indications. Founded in 2020-2021 and headquartered in Monmouth Junction, New Jersey, the company operates a vertically integrated spatial biology and anaerobic manufacturing platform anchored by HiPR-FISH (a high-plex spatial fluorescence in situ hybridization technology exclusively licensed from Cornell University) and ACT (Anaerobic Co-Culture Technology) acquired from Federation Bio in October 2023. The company's proprietary Kanvas Spectral Lightsheet (KSL) microscope enables high-throughput 3D spectral imaging at data acquisition rates reported to be at least 820x faster than commercial platforms, feeding proprietary AI/ML models (including Omnipose-based U-net segmentation) trained on what management describes as the world's largest spatial and functional host-microbiome dataset.

The platform supports four pillars — Characterization, Selection, Manufacturing, and Translation — and feeds a pipeline of rationally designed, defined microbial consortia including KAN-001 (preclinical, checkpoint-naïve and refractory cancers, co-developed with MD Anderson PRIME-TR), KAN-003 (preclinical, ICI-naïve cancers), KAN-004 (Phase 1, ICI-induced colitis at CRCHUM, First Patient In March 2026), and KAN-007 (Discovery, environmental enteric dysfunction with the Gates Foundation). Kanvas has demonstrated the ability to manufacture complex consortia of up to 148 bacterial strains reproducibly at scale (5L to 250L) in its ~4,000 sq ft GMP facility in South San Francisco, supplemented by a Princeton, NJ GMP suite.

The business combines a proprietary drug-development pipeline with a fee-for-service CDMO offering: Kanvas markets fully anaerobic GMP manufacturing and analytical services (microbial enumeration, strain-resolved viability, low-biomass detection, microbiome spatial mapping, strain-resolved metagenomic tracking) to external biotech and pharmaceutical clients developing LBPs, with GMP slots available from Q3 2026. Total capital raised is approximately $78M across a $12M Pre-Series A (June 2023, led by DCVC), a $12.5M extension (July 2024, co-led by DCVC and Lions Capital), and a $48M Series A (May 2026, co-led by DCVC and Lions Capital, with Gates Foundation participation). The company is pre-revenue on therapeutic products, has 11-50 employees, and sells into pharmaceutical/biotech CDMO clients and academic medical center partners including MD Anderson, CRCHUM, Cornell, and the Gates Foundation.

Short descriptiontext

Kanvas Biosciences is a clinical-stage biotech that maps host-microbiome interactions using proprietary HiPR-FISH spatial imaging and manufactures defined live biotherapeutic products (LBPs) for immuno-oncology, ICI-induced colitis, and global health indications, while offering anaerobic GMP CDMO services to biotech and pharma clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microbiome therapeutics discovery, live biotherapeutic products, spatial biology platform, GMP microbial manufacturing, microbiome CDMO services
Industry4 codes
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Microbiome Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO Services (Anaerobic Microbial Fermentation)
TypeManaged Services
Description

Revenue stream from contract development and manufacturing organization (CDMO) services for live biotherapeutic products (LBPs). Provides fully anaerobic GMP manufacturing for Phase 1 and Phase 2 clinical programs and GLP toxicology studies. Also offers standalone analytical services (microbial enumeration, strain-resolved viability, low-biomass microbial detection, microbiome spatial mapping, strain-resolved metagenomic tracking). Batch sizes up to 250L. GMP slots available beginning Q3 2026.

kanvasbio.com
2Professional Services / Discovery Partnerships
TypeProfessional Services
Description

Revenue from discovery partnerships with pharmaceutical and biotechnology companies seeking to better understand the microbiome and its role in disease and drug candidates. Includes spatial mapping services, microbial enumeration, metagenomic analysis, and analytical development using proprietary HiPR-FISH and related platforms.

kanvasbio.com
3Future Therapeutic Product Sales (Pre-revenue)
TypeOne Time License
Description

Currently pre-revenue on proprietary drug products. Lead drug KAN-001 entering Phase 1; KAN-004 in Phase 1 for ICI-induced colitis; KAN-007 in Discovery in partnership with Gates Foundation for environmental enteric dysfunction. Future revenue expected from commercialization of these live biotherapeutic products targeting immuno-oncology and global health indications.

pulse2.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain, Others
Pricing details2 tiers
1CDMO Manufacturing Services (Quote-based)
ModelOtherBilling cadenceMulti-year contract
Notes

Fully anaerobic GMP manufacturing for Phase 1 & 2 clinical trials and GLP toxicology studies; batch sizes up to 250L; GMP manufacturing slots available beginning Q3 2026; pricing is not publicly disclosed.

kanvasbio.com
2Analytical & Discovery Services (Quote-based)
ModelOtherBilling cadenceMulti-year contract
Notes

Standalone microbial enumeration, strain-resolved viability, low-biomass microbial detection, microbiome spatial mapping, and strain-resolved metagenomic tracking services. Pricing not publicly disclosed.

kanvasbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Kanvas Biosciences is a clinical-stage biotechnology company that develops live biotherapeutic products (LBPs) using a vertically-integrated platform combining proprietary spatial biology imaging (HiPR-FISH) with anaerobic co-culture manufacturing (ACT). The company also offers GMP microbial CDMO manufacturing services to external biotech and pharma partners, and conducts discovery and research partnerships with pharmaceutical companies such as Bayer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • 3 of 15 (20%) patients responded to FMT treatment in MD Anderson Phase 2 trial; 1 CRC patient achieved ongoing complete response >2 years
+8 more records
Product overview1 text field

Kanvas Biosciences operates a single unified spatial biology platform that vertically integrates four pillars—Characterization (HiPR-FISH spatial imaging of host-microbiome interactions), Selection (strain isolation, genomic and empirical screening, community building), Manufacturing (ACT™ anaerobic co-culture technology at industrial scale, operationalized in a ~4,000 sq ft GMP facility in South San Francisco), and Translation (metabolomic profiling, strain engraftment, host biomarker analysis). The platform feeds an in-house pipeline of live biotherapeutic product candidates—KAN-001 (checkpoint naïve and refractory cancers, preclinical with MD Anderson), KAN-003 (ICI-naïve cancers), KAN-004 (checkpoint-induced colitis, Phase 1 at CRCHUM), and KAN-007 (environmental enteric dysfunction with the Gates Foundation)—and is also offered to external clients as a fully anaerobic GMP microbial fermentation CDMO service with batch sizes up to 250 L.

Product and service6 records
1Kanvas Spatial Biology Platform
CategoryMicrobiome Therapeutics Platform
Description

A vertically-integrated spatial biology platform combining HiPR-FISH high-resolution spatial microbiome imaging, AI/ML hyperspectral image analysis, ACT anaerobic co-culture manufacturing, and the proprietary KSL microscope to discover, develop, and manufacture live biotherapeutic products. Used internally by Kanvas's pipeline teams and offered to external partners via discovery and research collaborations.

2Kanvas CDMO Manufacturing Services
CategoryMicrobial CDMO Services
Description

GMP-grade contract development and manufacturing organization (CDMO) services for live biotherapeutic products, engineered microbial therapies, and complex anaerobic co-culture manufacturing processes, operated from the company's GMP facility in South San Francisco, California. Offered to biotech and pharmaceutical companies needing industrial-scale anaerobic manufacturing capacity.

3KAN-001
CategoryImmuno-Oncology Live Biotherapeutic Product
Description

Live biotherapeutic product (LBP) candidate for the treatment of checkpoint naïve and refractory cancers, being developed in collaboration with MD Anderson Cancer Center. Currently in preclinical development.

4KAN-003
CategoryImmuno-Oncology Live Biotherapeutic Product
Description

Live biotherapeutic product (LBP) candidate for cancer indications, currently in preclinical development.

5KAN-004
CategoryGastroenterology Live Biotherapeutic Product
Description

Live biotherapeutic product (LBP) candidate for the treatment of immune checkpoint inhibitor (ICI)-induced colitis, which has received FDA Fast Track designation. Currently in Phase 1 clinical development at Vanderbilt and other sites.

6KAN-007
CategoryGlobal Health Live Biotherapeutic Product
Description

Live biotherapeutic product (LBP) candidate for the treatment of environmental enteric dysfunction (EED), a disease of poverty affecting children in low- and middle-income countries. Currently in discovery stage with support from the Bill & Melinda Gates Foundation.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Centre de recherche du CHUM (CRCHUM) / CHUM Microbiome Centre
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Strategic clinical partner sponsoring and hosting the Phase 1 trial of KAN-004 for ICI-induced colitis in Montreal. Collaboration with CHUM Microbiome Centre Directors Dr. Arielle Elkrief and Bertrand Routy. First Patient In achieved March 2026. Builds on the successful Phase 2 FMT-LUMINate trial.

kanvasbio.com
2Harvard Medical School (Keith Flaherty)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-03-17
Description

Dr. Keith Flaherty of Harvard Medical School serves on Kanvas Biosciences' Scientific Advisory Board (joined March 2025).

kanvasbio.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-11
Description

Strategic co-development partnership via the Platform for Innovative Microbiome and Translational Research (PRIME-TR). Collaborative work on KAN-001 (lead immuno-oncology drug candidate) and KAN-003, including preclinical studies, drug manufacturing, and FMT clinical trial that de-risks KAN-001 development. PRIME-TR director Dr. Jennifer Wargo has publicly endorsed the partnership.

4Federation Bio (assets acquired)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-10-11
Description

In October 2023, Kanvas Biosciences acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio. This transitioned Kanvas from a technology company to a full-stack therapeutics company with active clinical programs and a new cell banking facility in South San Francisco. Lee Swem (Federation Bio's former CSO) joined as Chief Development Officer.

kanvasbio.com
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Kanvas Biosciences' HiPR-FISH technology was initially developed at Cornell University by co-founder Iwijn De Vlaminck and CTO Hao Shi, and is exclusively licensed from Cornell. Cornell professor Iwijn De Vlaminck is co-founder and Chair of Scientific Advisory Board.

6Biotech / Pharmaceutical CDMO Clients
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Kanvas provides CDMO services to biotech clients seeking high-quality anaerobic microbial manufacturing supporting Phase 1 & 2 clinical trials or GLP tox studies. Targets clients needing anaerobic microbial consortia manufacturing that they cannot perform in-house. Per Platform page, Kanvas works with 'some of the top biotechnology and pharmaceutical companies in the scientific community.'

kanvasbio.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. George Church of the Wyss Institute serves on Kanvas Biosciences' Scientific Advisory Board.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Zain Kassam, co-founder of Finch Therapeutics and OpenBiome, serves on Kanvas Biosciences' Scientific Advisory Board.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

European clinical-stage microbiome therapeutics company with approved MaaT013 and pipeline in Graft-versus-Host Disease and oncology; comparable as a defined-consortium LBP developer targeting immuno-oncology complications.

TypeBroad incumbent
Description

Clinical-stage biotechnology company with a microbiome program (ABI-M201) for ulcerative colitis; broader portfolio reduces focus on microbiome relative to Kanvas.

TypeBroad incumbent
Description

UK-listed clinical-stage microbiome company with Live Biotherapeutic Products in oncology and respiratory disease; competes with Kanvas in LBP clinical development and platform breadth.

TypeDirect peer
Description

Pioneer in microbiome therapeutics with approved product VOWST and clinical pipeline; competes head-to-head with Kanvas in defined consortia LBP development, including oncology supportive-care adjacencies.

TypeBroad incumbent
Description

Ferring's microbiome subsidiary that developed RBX2660 (now Rebyota), the first FDA-approved FMT-based microbiome therapeutic; a broad incumbent with established GMP and commercial infrastructure Kanvas lacks.

TypeOthers
Description

Spatial biology platform company (Xenium, Visium); Kanvas's new VP of BD Steve Kujawa came from 10x and Kanvas's HiPR-FISH/KSL imaging overlaps with the broader spatial-omics tooling ecosystem.

TypeEmerging player
Description

Clinical-stage microbiome company developing defined consortia for asthma and inflammatory diseases; overlaps with Kanvas on the rationale of rationally designed microbial therapeutics.

8Federation Bio
TypeOthers
Description

Predecessor LBP company whose assets, IP, microbial library, and key personnel (Lee Swem, Aditya Bhalla, Marguerite Prior, Kyle Jacoby) were acquired by Kanvas in October 2023; remains the closest institutional comparator for Kanvas's manufacturing and regulatory capabilities.

TypeDirect peer
Description

Microbiome therapeutics company developing Full-Spectrum Microbiota and targeted consortia (FIN-211, etc.) for IBD and CDI; co-founder Zain Kassam sits on Kanvas's SAB, indicating close scientific overlap.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia (VE303, VE202) manufactured under GMP. Most direct competitor to Kanvas on defined consortia LBP manufacturing and clinical development.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kanvas Biosciences

Microbiome Therapeuticskanvasbio.com

Kanvas Biosciences is a clinical-stage biotech that maps host-microbiome interactions using proprietary HiPR-FISH spatial imaging and manufactures defined live biotherapeutic products (LBPs) for immuno-oncology, ICI-induced colitis, and global health indications, while offering anaerobic GMP CDMO services to biotech and pharma clients.

What Kanvas Biosciences does

Kanvas Biosciences is a clinical-stage biotechnology company developing live biotherapeutic products (LBPs) for immuno-oncology, immune-related adverse events, and global health indications. Founded in 2020-2021 and headquartered in Monmouth Junction, New Jersey, the company operates a vertically integrated spatial biology and anaerobic manufacturing platform anchored by HiPR-FISH (a high-plex spatial fluorescence in situ hybridization technology exclusively licensed from Cornell University) and ACT (Anaerobic Co-Culture Technology) acquired from Federation Bio in October 2023. The company's proprietary Kanvas Spectral Lightsheet (KSL) microscope enables high-throughput 3D spectral imaging at data acquisition rates reported to be at least 820x faster than commercial platforms, feeding proprietary AI/ML models (including Omnipose-based U-net segmentation) trained on what management describes as the world's largest spatial and functional host-microbiome dataset.

The platform supports four pillars — Characterization, Selection, Manufacturing, and Translation — and feeds a pipeline of rationally designed, defined microbial consortia including KAN-001 (preclinical, checkpoint-naïve and refractory cancers, co-developed with MD Anderson PRIME-TR), KAN-003 (preclinical, ICI-naïve cancers), KAN-004 (Phase 1, ICI-induced colitis at CRCHUM, First Patient In March 2026), and KAN-007 (Discovery, environmental enteric dysfunction with the Gates Foundation). Kanvas has demonstrated the ability to manufacture complex consortia of up to 148 bacterial strains reproducibly at scale (5L to 250L) in its ~4,000 sq ft GMP facility in South San Francisco, supplemented by a Princeton, NJ GMP suite.

The business combines a proprietary drug-development pipeline with a fee-for-service CDMO offering: Kanvas markets fully anaerobic GMP manufacturing and analytical services (microbial enumeration, strain-resolved viability, low-biomass detection, microbiome spatial mapping, strain-resolved metagenomic tracking) to external biotech and pharmaceutical clients developing LBPs, with GMP slots available from Q3 2026. Total capital raised is approximately $78M across a $12M Pre-Series A (June 2023, led by DCVC), a $12.5M extension (July 2024, co-led by DCVC and Lions Capital), and a $48M Series A (May 2026, co-led by DCVC and Lions Capital, with Gates Foundation participation). The company is pre-revenue on therapeutic products, has 11-50 employees, and sells into pharmaceutical/biotech CDMO clients and academic medical center partners including MD Anderson, CRCHUM, Cornell, and the Gates Foundation.

Kanvas Biosciences firmographics

Firmographics
Name
Kanvas Biosciences
Legal name
Kanvas Biosciences, Inc.
Website
https://kanvasbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Kanvas Biosciences is a clinical-stage biotech that maps host-microbiome interactions using proprietary HiPR-FISH spatial imaging and manufactures defined live biotherapeutic products (LBPs) for immuno-oncology, ICI-induced colitis, and global health indications, while offering anaerobic GMP CDMO services to biotech and pharma clients.
Ownership category
akta.pro rank

Kanvas Biosciences industry classification

Industry
Product category
Microbiome Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAFAA
Live Biotherapeutic Products (LBPs)
SECONDARYHLAAAFAJ
Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery)
SECONDARYHLAAAFAD
Engineered Microbial Therapeutics (synthetic biology, gene circuits)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms

Keywords

  • Microbiome therapeutics discovery
  • Live biotherapeutic products
  • Spatial biology platform
  • GMP microbial manufacturing
  • Microbiome CDMO services

Where Kanvas Biosciences is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kanvas Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain, Others

Revenue model

  1. CDMO Services (Anaerobic Microbial Fermentation): Revenue stream from contract development and manufacturing organization (CDMO) services for live biotherapeutic products (LBPs). Provides fully anaerobic GMP manufacturing for Phase 1 and Phase 2 clinical programs and GLP toxicology studies. Also offers standalone analytical services (microbial enumeration, strain-resolved viability, low-biomass microbial detection, microbiome spatial mapping, strain-resolved metagenomic tracking). Batch sizes up to 250L. GMP slots available beginning Q3 2026.
  2. Professional Services / Discovery Partnerships: Revenue from discovery partnerships with pharmaceutical and biotechnology companies seeking to better understand the microbiome and its role in disease and drug candidates. Includes spatial mapping services, microbial enumeration, metagenomic analysis, and analytical development using proprietary HiPR-FISH and related platforms.
  3. Future Therapeutic Product Sales (Pre-revenue): Currently pre-revenue on proprietary drug products. Lead drug KAN-001 entering Phase 1; KAN-004 in Phase 1 for ICI-induced colitis; KAN-007 in Discovery in partnership with Gates Foundation for environmental enteric dysfunction. Future revenue expected from commercialization of these live biotherapeutic products targeting immuno-oncology and global health indications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCDMO Manufacturing Services (Quote-based)
OtherMulti-year contractAnalytical & Discovery Services (Quote-based)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels10 records

Kanvas Biosciences product offering

Product offering

Core offering

Kanvas Biosciences is a clinical-stage biotechnology company that develops live biotherapeutic products (LBPs) using a vertically-integrated platform combining proprietary spatial biology imaging (HiPR-FISH) with anaerobic co-culture manufacturing (ACT). The company also offers GMP microbial CDMO manufacturing services to external biotech and pharma partners, and conducts discovery and research partnerships with pharmaceutical companies such as Bayer.

Product overview

Kanvas Biosciences operates a single unified spatial biology platform that vertically integrates four pillars—Characterization (HiPR-FISH spatial imaging of host-microbiome interactions), Selection (strain isolation, genomic and empirical screening, community building), Manufacturing (ACT™ anaerobic co-culture technology at industrial scale, operationalized in a ~4,000 sq ft GMP facility in South San Francisco), and Translation (metabolomic profiling, strain engraftment, host biomarker analysis). The platform feeds an in-house pipeline of live biotherapeutic product candidates—KAN-001 (checkpoint naïve and refractory cancers, preclinical with MD Anderson), KAN-003 (ICI-naïve cancers), KAN-004 (checkpoint-induced colitis, Phase 1 at CRCHUM), and KAN-007 (environmental enteric dysfunction with the Gates Foundation)—and is also offered to external clients as a fully anaerobic GMP microbial fermentation CDMO service with batch sizes up to 250 L.

Differentiator

Problem solved

Functional benefit

Products and services

  • Kanvas Spatial Biology Platform A vertically-integrated spatial biology platform combining HiPR-FISH high-resolution spatial microbiome imaging, AI/ML hyperspectral image analysis, ACT anaerobic co-culture manufacturing, and the proprietary KSL microscope to discover, develop, and manufacture live biotherapeutic products. Used internally by Kanvas's pipeline teams and offered to external partners via discovery and research collaborations.
  • Kanvas CDMO Manufacturing Services GMP-grade contract development and manufacturing organization (CDMO) services for live biotherapeutic products, engineered microbial therapies, and complex anaerobic co-culture manufacturing processes, operated from the company's GMP facility in South San Francisco, California. Offered to biotech and pharmaceutical companies needing industrial-scale anaerobic manufacturing capacity.
  • KAN-001 Live biotherapeutic product (LBP) candidate for the treatment of checkpoint naïve and refractory cancers, being developed in collaboration with MD Anderson Cancer Center. Currently in preclinical development.
  • KAN-003 Live biotherapeutic product (LBP) candidate for cancer indications, currently in preclinical development.
  • KAN-004 Live biotherapeutic product (LBP) candidate for the treatment of immune checkpoint inhibitor (ICI)-induced colitis, which has received FDA Fast Track designation. Currently in Phase 1 clinical development at Vanderbilt and other sites.
  • KAN-007 Live biotherapeutic product (LBP) candidate for the treatment of environmental enteric dysfunction (EED), a disease of poverty affecting children in low- and middle-income countries. Currently in discovery stage with support from the Bill & Melinda Gates Foundation.

Quantifiable outcome

  • 3 of 15 (20%) patients responded to FMT treatment in MD Anderson Phase 2 trial; 1 CRC patient achieved ongoing complete response >2 years
  • +8 more outcomes

Companies that use Kanvas Biosciences

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Kanvas Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Kanvas Biosciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship, minor and core.

  • Centre de recherche du CHUM (CRCHUM) / CHUM Microbiome CentreflagshipStrategic or Co-development Partner · 23 March 2026Strategic clinical partner sponsoring and hosting the Phase 1 trial of KAN-004 for ICI-induced colitis in Montreal. Collaboration with CHUM Microbiome Centre Directors Dr. Arielle Elkrief and Bertrand Routy. First Patient In achieved March 2026. Builds on the successful Phase 2 FMT-LUMINate trial.
  • Harvard Medical School (Keith Flaherty)minorStrategic or Co-development Partner · 17 March 2025Dr. Keith Flaherty of Harvard Medical School serves on Kanvas Biosciences' Scientific Advisory Board (joined March 2025).
  • The University of Texas MD Anderson Cancer Center (PRIME-TR)flagshipStrategic or Co-development Partner · 11 October 2023Strategic co-development partnership via the Platform for Innovative Microbiome and Translational Research (PRIME-TR). Collaborative work on KAN-001 (lead immuno-oncology drug candidate) and KAN-003, including preclinical studies, drug manufacturing, and FMT clinical trial that de-risks KAN-001 development. PRIME-TR director Dr. Jennifer Wargo has publicly endorsed the partnership.
  • Federation Bio (assets acquired)flagshipStrategic or Co-development Partner · 11 October 2023In October 2023, Kanvas Biosciences acquired two active therapeutics programs, a microbial library, and intellectual property from Federation Bio. This transitioned Kanvas from a technology company to a full-stack therapeutics company with active clinical programs and a new cell banking facility in South San Francisco. Lee Swem (Federation Bio's former CSO) joined as Chief Development Officer.
  • Cornell UniversityflagshipStrategic or Co-development PartnerKanvas Biosciences' HiPR-FISH technology was initially developed at Cornell University by co-founder Iwijn De Vlaminck and CTO Hao Shi, and is exclusively licensed from Cornell. Cornell professor Iwijn De Vlaminck is co-founder and Chair of Scientific Advisory Board.
  • Biotech / Pharmaceutical CDMO ClientscoreChannel Partner/ Reseller/ DistributorKanvas provides CDMO services to biotech clients seeking high-quality anaerobic microbial manufacturing supporting Phase 1 & 2 clinical trials or GLP tox studies. Targets clients needing anaerobic microbial consortia manufacturing that they cannot perform in-house. Per Platform page, Kanvas works with 'some of the top biotechnology and pharmaceutical companies in the scientific community.'
  • Wyss Institute (George Church)minorStrategic or Co-development PartnerDr. George Church of the Wyss Institute serves on Kanvas Biosciences' Scientific Advisory Board.
  • Finch Therapeutics / OpenBiome (Zain Kassam)minorStrategic or Co-development PartnerDr. Zain Kassam, co-founder of Finch Therapeutics and OpenBiome, serves on Kanvas Biosciences' Scientific Advisory Board.

Scale indicators17 records

Recent moves8 records

Expansion highlights6 records

Kanvas Biosciences competitors and assessment

Company assessment

Direct peers

  • MaaT Pharma: European clinical-stage microbiome therapeutics company with approved MaaT013 and pipeline in Graft-versus-Host Disease and oncology; comparable as a defined-consortium LBP developer targeting immuno-oncology complications.
  • Seres Therapeutics: Pioneer in microbiome therapeutics with approved product VOWST and clinical pipeline; competes head-to-head with Kanvas in defined consortia LBP development, including oncology supportive-care adjacencies.
  • Finch Therapeutics: Microbiome therapeutics company developing Full-Spectrum Microbiota and targeted consortia (FIN-211, etc.) for IBD and CDI; co-founder Zain Kassam sits on Kanvas's SAB, indicating close scientific overlap.
  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia (VE303, VE202) manufactured under GMP. Most direct competitor to Kanvas on defined consortia LBP manufacturing and clinical development.

Broad incumbents

  • Assembly Biosciences: Clinical-stage biotechnology company with a microbiome program (ABI-M201) for ulcerative colitis; broader portfolio reduces focus on microbiome relative to Kanvas.
  • 4D pharma: UK-listed clinical-stage microbiome company with Live Biotherapeutic Products in oncology and respiratory disease; competes with Kanvas in LBP clinical development and platform breadth.
  • Rebiotix (Ferring Pharmaceuticals): Ferring's microbiome subsidiary that developed RBX2660 (now Rebyota), the first FDA-approved FMT-based microbiome therapeutic; a broad incumbent with established GMP and commercial infrastructure Kanvas lacks.

Others

  • 10x Genomics: Spatial biology platform company (Xenium, Visium); Kanvas's new VP of BD Steve Kujawa came from 10x and Kanvas's HiPR-FISH/KSL imaging overlaps with the broader spatial-omics tooling ecosystem.
  • Federation Bio: Predecessor LBP company whose assets, IP, microbial library, and key personnel (Lee Swem, Aditya Bhalla, Marguerite Prior, Kyle Jacoby) were acquired by Kanvas in October 2023; remains the closest institutional comparator for Kanvas's manufacturing and regulatory capabilities.

Emerging players

  • Siolta Therapeutics: Clinical-stage microbiome company developing defined consortia for asthma and inflammatory diseases; overlaps with Kanvas on the rationale of rationally designed microbial therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Kanvas Biosciences social profiles

Digital presence

Kanvas Biosciences compliance and trust

Trust signal

Compliance3 records

Kanvas Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kanvas Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Kanvas Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kanvas Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kanvas Biosciences

What does Kanvas Biosciences do?

Kanvas Biosciences is a clinical-stage biotechnology company that develops live biotherapeutic products (LBPs) using a vertically-integrated platform combining proprietary spatial biology imaging (HiPR-FISH) with anaerobic co-culture manufacturing (ACT). The company also offers GMP microbial CDMO manufacturing services to external biotech and pharma partners, and conducts discovery and research partnerships with pharmaceutical companies such as Bayer.

Is Kanvas Biosciences a public or private company?

Kanvas Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kanvas Biosciences founded?

Kanvas Biosciences was founded in 2020. It employs 11 to 50 people.

Where is Kanvas Biosciences based?

Kanvas Biosciences is headquartered in Princeton, United States, in the North America region.

How does Kanvas Biosciences make money?

Three revenue lines are on record. CDMO Services (Anaerobic Microbial Fermentation) is the primary driver. The others are professional Services / Discovery Partnerships and future Therapeutic Product Sales (Pre-revenue).

Who are Kanvas Biosciences's main competitors?

Direct peers on record are MaaT Pharma, Seres Therapeutics, Finch Therapeutics and Vedanta Biosciences. Broad incumbents are Assembly Biosciences, 4D pharma and Rebiotix (Ferring Pharmaceuticals). Others are 10x Genomics and Federation Bio. Siolta Therapeutics is listed as an emerging player.

Does Kanvas Biosciences have an API?

No public API is recorded for Kanvas Biosciences.

What industry is Kanvas Biosciences in?

Kanvas Biosciences's product category is Microbiome Therapeutics. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NJBIZRoundup: Hackensack Meridian debuts brain imaging drug; Kanvas joins HELIXHackensack Meridian Health became the first Northeast hospital network to use Pixclara, an FDA-approved PET imaging drug for brain cancer, at its Hoboken Imaging Services center. The drug combines with MRI to yield 41% higher diagnostic accuracy. Kanvas Biosciences relocated its lab to The HELIX in New Brunswick after closing a $48M Series A round.Prtimes日本ゼオン、Kanvas Biosciencesへ投資Zeon Corporation has invested in Kanvas Biosciences, a pharmaceutical development company based in Princeton, New Jersey, through its subsidiary Zeon Ventures Inc. in California. Kanvas is described as the world's first drug discovery startup developing and manufacturing pharmaceuticals using intestinal microbiome technology with unique spatial biology capabilities. This investment advances Zeon's STAGE30 mid-term management plan, specifically strengthening its "medical and life sciences" growth sector, as the company seeks to establish new business opportunities in the microbiome-related market.Cornell ChronicleKanvas Biosciences raises $48 million to advance microbiome cancer therapiesKanvas Biosciences has raised $48 million in Series A funding, co-led by DCVC and Lions Capital, to advance its microbiome-based cancer immunotherapy and support a clinical trial later this year. The company's lead therapy is based on roughly 50 bacterial strains isolated from a 76-year-old stage 4 colorectal cancer patient who achieved complete recovery after Keytruda treatment. Kanvas is also developing therapies for immunotherapy-induced colon inflammation and environmental enteric dysfunction, with the latter being pursued in partnership with the Gates Foundation.Cornell ChronicleCornell CAT convenes researchers, industry to accelerate life sciences innovationCornell's Center for Advanced Technology (CAT) in Life Science Enterprise held a daylong event on April 29 to promote academic-industry collaboration, drawing faculty, researchers, entrepreneurs, and industry partners from across New York State to discuss moving discoveries toward commercialization. Keynote speakers included IN8bio COO Kate Rochlin and Cornell professor Iwijn De Vlaminck, who is co-founder of Kanvas Biosciences and Romix Biosciences, alongside panel discussions featuring CEOs from Persista Bio and BioSpherix. Cornell reported launching 20 technology-based companies last year and maintaining over 500 active industry partnerships, while promoting its CAT Grants program offering $75,000 awards matched one-to-one by industry partners for collaborative projects.BioPharm InternationalFunding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer ImmunotherapiesKanvas Biosciences closed a $48 million Series A led by DCVC and Lions Capital, bringing total funding to about $78 million. LTZ Therapeutics raised $38 million to advance myeloid engager immunotherapy. The combined $86 million will support clinical trials and platform development for microbiome and innate immune-targeted cancer treatments.ForbesThe Gates Foundation Is Funding A Startup’s Plan To Fight Malnutrition With BacteriaKanvas Biosciences received new funding from the Bill & Melinda Gates Foundation to develop a synthetic bacterial microbiome treatment for environmental enteric dysfunction (EED), a condition affecting approximately 150 million children worldwide that causes severe gut inflammation and prevents nutrient absorption. The company's technology can pack 145 different bacterial strains into a single pill, significantly more than other microbiome treatments that typically contain fewer than a dozen strains. Kanvas has one treatment currently in clinical trials and another entering trials later this year, with the treatments initially designed for pregnant women to induce healing in mothers and provide healthy microbiomes for their unborn infants.citybizKanvas Biosciences Secures Gates Foundation Funding for Synthetic Microbiome Therapy ProgramKanvas Biosciences has received funding from the Gates Foundation to develop what the company claims would be the world's first fully synthetic microbiome replacement therapy for maternal environmental enteric dysfunction, a chronic inflammatory intestinal disorder affecting approximately 150 million children worldwide and linked to malnutrition and poor maternal and infant health outcomes. The Princeton, New Jersey-based company plans to use the funding to advance its live biotherapeutic product combining microbiome mapping, spatial biology, AI-driven drug discovery, and anaerobic manufacturing to create multi-strain bacterial consortia. The initiative reflects growing global health interest in microbiome-based medicine as an alternative to conventional pharmaceuticals for addressing gut health, nutrient absorption, and developmental deficits in low-resource regions.pharmaphorumWindward raises $165m for TSLP drug, and other biofinancingsWindward Bio raised $165 million in crossover financing to extend its cash runway for clinical trials of its TSLP inhibitor WIN378. The drug, licensed from Kelun-Biotech, is in phase 2/3 for asthma, with phase 2 dosing data expected later this year. The round brings total funding above $365 million.Business Wire BlogKanvas Biosciences Receives New Funding to Develop First-In-Category Microbiome Therapeutic for Improving Maternal, Newborn and Child HealthKanvas Biosciences received Gates Foundation funding to develop a synthetic microbiome therapeutic for treating and preventing environmental enteric dysfunction (EED) in pregnant persons across Southern Asia and Sub-Saharan Africa. EED affects about 150 million children and causes intestinal inflammation and poor nutrient absorption. The company plans clinical evaluation in relevant geographical contexts.Pulse 2.0Kanvas Biosciences: $48 Million Series A Raised For Microbiome Cancer Therapeutics PlatformKanvas Biosciences announced the close of a $48 million Series A financing round, co-led by DCVC and Lions Capital LLC with participation from Gates Foundation and other investors, to advance its microbiome therapeutics platform for cancer patients. The funding brings the company's total capital raised to $78 million and will support clinical trials for lead drug candidate KAN-001, designed to improve immunotherapy outcomes in cancer patients who do not respond to immune checkpoint inhibitors. The company is also preparing for patient recruitment in a Phase 1 clinical trial for KAN-004, targeting immune checkpoint inhibitor-induced colitis.